Abstract

Synaptic loss is the earliest pathological change in Alzheimer disease (AD) and is the pathological change most directly correlated with the degree of dementia. ApoE4 is the major genetic risk factor for the age-dependent form of AD, which accounts for 95% of cases. Here we show that in synaptic networks formed from primary hippocampal neurons in culture, apoE3, but not apoE4, prevents the loss of synaptic networks produced by amyloid β oligomers (amylospheroids). Specific activators of PKCε, such as 8-(2-(2-pentyl-cyclopropylmethyl)-cyclopropyl)-octanoic acid methyl ester and bryostatin 1, protected against synaptic loss by amylospheroids, whereas PKCε inhibitors blocked this synaptic protection and also blocked the protection by apoE3. Blocking LRP1, an apoE receptor on the neuronal membrane, also blocked the protection by apoE. ApoE3, but not apoE4, induced the synthesis of PKCε mRNA and expression of the PKCε protein. Amyloid β specifically blocked the expression of PKCε but had no effect on other isoforms. These results suggest that protection against synaptic loss by apoE is mediated by a novel intracellular PKCε pathway. This apoE pathway may account for much of the protective effect of apoE and reduced risk for the age-dependent form of AD. This finding supports the potential efficacy of newly developed therapeutics for AD.

Highlights

  • Introduction of human apolipoproteinE4 “domain interaction” into mouse apolipoprotein E

  • Before analyzing the toxicity of these ASPDs and A␤-derived diffusible ligands (ADDLs), we verified the size of 100-kDa retentates (ASPDs) and ADDLs by size exclusion chromatography

  • We found that the size of these ASPDs was ϳ175 kDa (Fig. 1A) when compared with the size standards subjected to size exclusion chromatography, whereas ADDLs showed peaks at 18, 16, and 8 kDa

Read more

Summary

Background

ApoE4 is a genetic risk factor for sporadic AD. PKC is involved in synaptogenesis and shows abnormalities in aging and AD. ApoE4 is the major genetic risk factor for the age-dependent form of AD, which accounts for 95% of cases. Amyloid ␤ blocked the expression of PKC⑀ but had no effect on other isoforms These results suggest that protection against synaptic loss by apoE is mediated by a novel intracellular PKC⑀ pathway. This apoE pathway may account for much of the protective effect of apoE and reduced risk for the age-dependent form of AD. This finding supports the potential efficacy of newly developed therapeutics for AD. Individuals with two apoE ⑀4 alleles are at 3–10 times greater risk in developing AD

To whom correspondence should be addressed
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call